Carisma Therapeutics Inc.
3025 Market Street, Ste 140
About Carisma Therapeutics Inc.
Carisma Therapeutics is pioneering the development of CAR macrophages, a disruptive approach to immunotherapy. Our technology leverages advances in macrophage biology, chimeric antigen receptor engineering and adoptive cellular therapy for the treatment of human disease.
8 articles with Carisma Therapeutics Inc.
Phio Pharmaceuticals Announces Research Collaboration with Carisma Therapeutics to Evaluate its Self-Delivering RNAi Technology to Enhance Macrophage-Based Adoptive Cell Therapy
Collaboration may further expand the range of immune cells that can be 'weaponized' using Phio's gene silencing technology
Carisma Therapeutics Inc. announced Robert Petit, Ph.D., as its Chief Scientific Officer.
Carisma is a preclinical-stage biopharmaceutical company focused on discovering and developing innovative immunotherapies based on chimeric antigen receptor macrophages
Carisma Therapeutics Announces a $53 Million Series A Financing to Develop Novel CAR Macrophage Cellular Immunotherapy
Initial applications to focus on the treatment of solid tumor malignancies
AbbVie Ventures, the investment arm of AbbVie, led a $53 million Series A funding round for Carisma Therapeutics and its immunotherapy CAR-Macrophage platform.
CARMA Therapeutics is based on technology from the Center for Cellular Immunotherapies at the University of Pennsylvania, and was spun out of the laboratory of Saar Gill, assistant professor of Hematology Oncology in the Perelman School of Medicine there.
BioSpace is proud to present its NextGen "Class of 2018," a list of 20 up-and-coming life science companies in North America that started up no earlier than 2015.